A detailed history of Cornercap Investment Counsel Inc transactions in Bio Atla, Inc. stock. As of the latest transaction made, Cornercap Investment Counsel Inc holds 61,200 shares of BCAB stock, worth $83,844. This represents 0.03% of its overall portfolio holdings.

Number of Shares
61,200
Previous 61,200 -0.0%
Holding current value
$83,844
Previous $150,000 40.0%
% of portfolio
0.03%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$1.7 - $3.07 $567 - $1,025
-334 Reduced 0.54%
61,200 $104,000
Q1 2023

May 11, 2023

BUY
$2.3 - $8.25 $66,649 - $239,068
28,978 Added 89.01%
61,534 $164,000
Q3 2022

Nov 14, 2022

SELL
$2.94 - $11.87 $43,629 - $176,150
-14,840 Reduced 31.31%
32,556 $251,000
Q2 2022

Aug 15, 2022

BUY
$2.13 - $5.38 $100,953 - $254,990
47,396 New
47,396 $135,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $49.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Cornercap Investment Counsel Inc Portfolio

Follow Cornercap Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornercap Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cornercap Investment Counsel Inc with notifications on news.